Cambridge Investment Research Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,192
| Closed | -$223K | – | 3293 |
|
|
2023
Q2 | $223K | Buy |
+2,192
| New | +$223K | ﹤0.01% | 2790 |
|
|
2021
Q4 | – | Sell |
-2,388
| Closed | -$240K | – | 3301 |
|
|
2021
Q3 | $240K | Buy |
2,388
+94
| +4% | +$9.45K | ﹤0.01% | 2647 |
|
|
2021
Q2 | $325K | Buy |
2,294
+67
| +3% | +$9.49K | ﹤0.01% | 2408 |
|
|
2021
Q1 | $222K | Buy |
2,227
+82
| +4% | +$8.17K | ﹤0.01% | 2533 |
|
|
2020
Q4 | $265K | Sell |
2,145
-200
| -9% | -$24.7K | ﹤0.01% | 2250 |
|
|
2020
Q3 | $228K | Sell |
2,345
-150
| -6% | -$14.6K | ﹤0.01% | 2151 |
|
|
2020
Q2 | $389K | Hold |
2,495
| – | – | ﹤0.01% | 1695 |
|
|
2020
Q1 | $360K | Buy |
2,495
+50
| +2% | +$7.21K | ﹤0.01% | 1565 |
|
|
2019
Q4 | $500K | Buy |
+2,445
| New | +$500K | ﹤0.01% | 1578 |
|